Moscow, October, 20 2008
Quantum and University of Pittsburgh announced a drug discovery collaboration in HIV sphere. Under the terms of agreement Quantum gets access to the target data from University of Pittsburgh. Quantum will apply its industry leading computational technology to discover novel small molecule inhibitors for this target. The University is to provide biological expertise and further develop the discovered inhibitors. The financial terms of the deal were not disclosed.
About Quantum
Quantum is a drug discovery company based in Moscow, Russia specializing in small molecule screening and design through the use of its proprietary technology platform.
About University of Pittsburgh
Founded in 1787 the University of Pittsburgh has evolved into an internationally recognized center of learning and research. The University’s 12,000 employees, including 3,800 full-time faculty members, serve about 34,000 students through the programs of 15 undergraduate, graduate, and professional schools.
More From fedichev
- Quantum Pharmaceuticals collaborates with Fox Chase Cancer Center on discovery of new small molecules inhibitors in cancer area.
- Quantum Pharmaceuticals and Institute of Pulmonology entered COPD drug discovery collaboration.
- Quantum Pharmaceuticals and Otechestvennye Lekarstva OJSC entered drug discovery collaboration.
Related posts:
- HIV-1 integrase drug discovery collaboration
- Quantum collaborates with Fox Chase Cancer Center on discovery of new small molecules inhibitors in cancer area.
- Quantum and Tibotec Pharmaceuticals enter antiviral drug discovery collabortaion.
- Quantum and Institute of Pulmonology entered COPD drug discovery collaboration.
- Quantum announce collaboration with University of Colorado at Boulder
